MAX
Company Analysis Laboratorios Farmaceuticos Rovi, S.A.
1. Summary
Advantages
- Dividends (2.73%) are higher than the sector average (1.66%).
- The stock's return over the last year (0%) is higher than the sector average (-33.77%).
- The company's current efficiency (ROE=21.14%) is higher than the sector average (ROE=15.15%)
Disadvantages
- Price (90.61 $) is higher than fair price (38.06 $)
- Current debt level 15.29% has increased over 5 years from 12.8%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Laboratorios Farmaceuticos Rovi, S.A. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -41.7% | -1.5% |
| 90 days | 0% | -43.7% | -1.6% |
| 1 year | 0% | -33.8% | 14.9% |
LABFF vs Sector: Laboratorios Farmaceuticos Rovi, S.A. has outperformed the "Healthcare" sector by 33.77% over the past year.
LABFF vs Market: Laboratorios Farmaceuticos Rovi, S.A. has significantly underperformed the market by -14.87% over the past year.
Stable price: LABFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LABFF with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (90.61 $) is higher than the fair price (38.06 $).
Price is higher than fair: The current price (90.61 $) is 58% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (33.01) is lower than that of the sector as a whole (33.16).
P/E vs Market: The company's P/E (33.01) is lower than that of the market as a whole (48.4).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (6.98) is higher than that of the sector as a whole (3.58).
P/BV vs Market: The company's P/BV (6.98) is higher than that of the market as a whole (3.23).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (6.24) is higher than that of the sector as a whole (3.72).
P/S vs Market: The company's P/S indicator (6.24) is lower than that of the market as a whole (11.95).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (23.02) is higher than that of the sector as a whole (15.06).
EV/Ebitda vs Market: The company's EV/Ebitda (23.02) is lower than that of the market as a whole (23.78).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -0.68% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-0.68%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-12.88%).
6.4. ROE
ROE vs Sector: The company's ROE (21.14%) is higher than that of the sector as a whole (15.15%).
ROE vs Market: The company's ROE (21.14%) is lower than that of the market as a whole (36.18%).
6.6. ROA
ROA vs Sector: The company's ROA (14.7%) is higher than that of the sector as a whole (7.73%).
ROA vs Market: The company's ROA (14.7%) is lower than that of the market as a whole (24.07%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (14.03%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.74%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
High yield: The dividend yield of the company 2.73% is higher than the average for the sector '1.66%.
8.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.73% has been steadily paid over the past 7 years, DSI=0.92.
Weak dividend growth: The company's dividend yield 2.73% has been growing weakly or stagnant over the past 5 years. Growth over only 4 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (34.06%) are at a comfortable level.
Based on sources: porti.ru
